What smart money is saying about Cidara Therapeutics, Inc.
1 fund in our archive has pitched Cidara Therapeutics, Inc., most recently Baron Health Care Fund in September 2025.
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Get an email when a fund buys, sells or pitches it
Position history
Between Q3 2025 and Q4 2025, 1 fund letter reported a position in Cidara Therapeutics, Inc., with 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q4 2025 | 1 | 0 | 1 | 0 |
| Q3 2025 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position · 1 move
- December 2025
“Health-care stocks accounted for several top contributors to Fund performance for the quarter. Among these were Exact Sciences Corp. (EXAS) and Cidara Therapeutics, Inc. (CDTX). Shares of both companies jumped after they agreed to be acquired by larger firms in all-cash deals expected to close in 2026. In our view, this activity is a constructive signal for the space, with larger buyers demonstrating a willingness to invest in high-quality assets within health care. We liquidated positions in both companies to lock in gains from the acquisitions and redeploy proceeds into other opportunities.”
Cidara Therapeutics, Inc.
Fund coverage · 1 thesis
- Baron Health Care FundSeptember 2025
Cidara Therapeutics, Inc. is developing a long-acting antiviral drug for flu prevention that has shown promising efficacy and safety in clinical trials, targeting a market of over 100 million people in the U.S.
Read the full thesis
Read every full thesis on Cidara Therapeutics, Inc.
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→